ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 0917

Role of Mutual Information Profile Shifts in Assessing the Pathogenicity of Mutations on Protein Functions: The Case of Pyrin Mutations in Familial Mediterranean Fever

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1238

Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in Those with Polymyalgia Rheumatica

Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1014

Rural-dwelling Patients with Rheumatoid Arthritis or Those with Lower Income Are More Likely to Be Admitted for Myocardial Infarction in the U.S. and Have Worse Outcomes

Healthcare Disparities in Rheumatology Poster II

10:30AM-12:30PM: Abstract Number: 1460

Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1392

Safety and Efficacy of Upadacitinib (UPA) in Japanese Patients with Rheumatoid Arthritis (RA) and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-SUNRISE Study

RA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1197

Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 1130

Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1173

Safety of Non-Exercise Rehabilitation Interventions for Adults with Rheumatoid Arthritis

Orthopedics, Low Back Pain, & Rehabilitation – ACR/ARP Poster

10:30AM-12:30PM: Abstract Number: 1481

Safety of Secukinumab in Patients with Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis and Hidradenitis Suppurativa: Updated Pooled Data from 69 Clinical Trials

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1553

Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)

SLE – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0931

Salivary Granular Convoluted Tubules Contribute to Maintain Tissue-specific Tolerance – Implications for the Development of Murine Sjögren´s Syndrome

Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 1409

Salivary Organoids Contain More Diverse Epithelial and Less Mesenchymal Cells Than Adherent Cultures: Choose Your Sjögren’s Disease Research Tool Carefully

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0936

Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis

Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0965

Scleroderma Associated Interstitial Lung Disease Is Characterized by Aberrant Lung Epithelial Remodeling

Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1569

Scleroderma Renal Crisis – Different Phenotypes and Patient Trajectories

Systemic Sclerosis & Related Disorders – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].